Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 875-877

  Ruyssen Witrand, A ^a,b   Rouanet, S ^c   Combe, B ^d   Dougados, M ^e   Le Loet X ^f   Sibilia, J ^g   Tebib, J ^h   Mariette, X ⁱ   Constantin, A ^a,b  

^a CHU PURPAN   (France)

^b CNRS   (France)

^c Roche   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PHENYLALANINE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VALINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; DRUG INFUSION; FC GAMMA RECEPTOR TYPE IIIA GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860898796     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200337     Document Type: Article

References (15)

1. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
2. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
3. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9. (Pubitemid 38856941)
4. Gragnani L, Piluso A, Giannini C, et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. Arthritis Rheum 2011;63:1446-51.
5. Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011;63:933-8.
6. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
7. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.
8. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7.
9. Cañete JD, Suárez B, Hernández MV, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1547-52.
10. Kastbom A, Bratt J, Ernestam S, et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:448-52.
11. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005;52:2693-6. (Pubitemid 41369097)
12. Quartuccio L, Lombardi S, Fabris M, et al. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann N Y Acad Sci 2009;1173:692-700.
13. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-4. (Pubitemid 47523179)
14. Cooper DL, Martin S, Kozera L, et al. Fcγ receptors as determinants of response to B cell depleting therapies in rheumatoid ar thritis. Ann Rheum Dis 2011;70:70.
15. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9. (Pubitemid 36278014)